Novotech

On October 25, Novotech participated in the Global Clinical Research Practices Seminar jointly hosted by the Canadian Embassy and the Korea Institute of Toxicology, at the Canadian Embassy’s Scofield Hall. Lilian K., Senior Director of Business Development at Novotech, led a key session on "Leveraging Australia to Accelerate Drug Development Globally," highlighting how Australia’s regulatory landscape and advanced clinical infrastructure can accelerate trials and facilitate global market entry. Lilian provided strategic pathways, collaboration benefits, and case studies illustrating Novotech’s role in helping clients achieve rapid development milestones. The seminar also provided valuable networking opportunities, with attendees engaging in pre-arranged consultations and discussions with industry leaders, including Lilian. #ClinicalTrials #AustraliaInResearch #Novotech

Thank you to everyone who joined us at OCT Nordics 2024 in Copenhagen. In his talk, “Empowering Patients to Overcome Challenges in Orphan Drug Development,” Scott Schliebner, VP of Drug Development Consulting, shared strategies for overcoming rare disease challenges, enhancing patient-centered trials, and reducing participation burdens. He also highlighted AI's expanding role in drug discovery and clinical trials, emphasizing its potential to streamline processes and reshape development. Watch the full interview video to catch Scott’s insights: https://lnkd.in/df_m8M9G #OCTNordics2024 #ClinicalTrials #Novotech

At the recent 2024 Frost & Sullivan Best Practices Awards Gala in Tucson, AZ, Novotech was honored as the 2024 Global Biotech Contract Research Organization Company of the Year. Accepting on behalf of Novotech were Toyna Chin, Global Director of Marketing, and Terra Johnston, Director of Regulatory Operations. The Frost & Sullivan Best Practices Awards recognize companies for exceptional achievement in leadership, innovation, customer service, and strategic development across regional and global markets. #FrostAndSullivan #CompanyOfTheYear #BestPracticesAwards

Europe’s regulatory landscape is undergoing significant transformation with the implementation of the new Clinical Trial Regulation (CTR) and Clinical Trial Information System (CTIS). These advancements aim to streamline trial approvals and harmonize processes across countries, unlocking new opportunities for clinical research. However, challenges in regional readiness, particularly for multi-country trials, remain. Gain insights into how these regulatory changes are reshaping clinical trials and explore the benefits and complexities facing sponsors throughout Europe. https://ow.ly/kwf150TWWaK #ClinicalTrials #RegulatoryAffairs #Novotech

Is your clinical trial ready to meet the FDA’s new diversity guidance? Join Novotech on November 19 at 2 p.m. ET for a webinar on "Implementing a Diversity Plan: Operational Considerations for Your Clinical Trial". Our expert panel: 🔹 Dr. Isaac R. Rodriguez-Chavez, PhD, MHSc, MSc 🔹 Dr. Chardae Rodgers-Gamble, CEO, CR Clinical, DBA, MS. 🔹 Danielle S. Mitchell, CEO and Founder, Black Women In Clinical Research ®. 🔹 Sarah Rose Anderson, Oncology Therapeutic Strategy Director, Novotech. Moderated by Dr. Judith Ng-Cashin, M.D., Chief Medical Officer at Novotech, the panel will explore recommendations on how and when to integrate diversity plans into your existing operational frameworks. Don’t miss this opportunity to ensure compliance and operational efficiency. Register here: https://lnkd.in/dFQdmHs5 #FDADiversityGuidance #Novotech #Webinar

Novotech has signed a Memorandum of Understanding (MOU) with Show Chwan Health Care System, one of the largest hospital chains in Taiwan, consisting of ten branch hospitals, including up to three tertiary hospitals of clinical trial sites with 24,000 beds. This collaboration, commemorated with a joint plaque unveiling ceremony, aims to enhance clinical trial quality and efficiency across the Asia-Pacific, supporting accelerated drug development and expanding patient treatment options. With extensive experience across 5,000+ global trials, Novotech will collaborate closely with Show Chwan’s established research infrastructure to foster innovation in clinical research. Read more: https://lnkd.in/guY6P29i Yooni Kim #ClinicalTrials #AsiaPacific #Novotech #ShowChwan

At Novotech we take pride in supporting your career. We offer development programs, mentorship, and diverse opportunities to help you achieve your career goals. Join us today! Find your next role: https://lnkd.in/gBX4Mmh2 #CRA #clinicaltrials #clinicalresearch #cro #lifeatnovotech

Wishing you all a joyous and bright Diwali! Today, our Novotech family joins millions around the world in celebrating this beautiful Festival of Lights. To all our employees, partners, and customers celebrating today: May this Diwali bring you prosperity, success, and happiness. #Diwali2024 #Lifeatnovotech #FestivalOfLights

Our US team is marking GPTW Certification Nation Day in style! We are proud to be certified as a Great Place to Work, an achievement made possible by every member of our amazing team. #GPTWCertificationNation #lifeatNovotech #ClinicalResearch

Novotech’s new Global Clinical Trial Landscape for Small Cell Lung Cancer (SCLC) report is now available. This report provides essential insights on trial distribution, emerging therapies, and regulatory trends in SCLC. Download the report to support data-driven decisions in your clinical strategy. Key takeaways from the report: 🔹Regional Distribution of Trials: Asia-Pacific leads SCLC clinical trials with 47% of the global share, showcasing the region's growth potential for oncology research, particularly in Mainland China, which represents 53% of Asia-Pacific trials. 🔹Emerging Therapeutic Strategies: SCLC treatment is shifting towards personalized approaches, including targeted therapies and immune checkpoint inhibitors (ICIs). New drug classes, such as BiTEs and PARP inhibitors, are evolving to address treatment-resistant SCLC. 🔹High Demand for Novel Treatments: The prevalence of ongoing trials in SCLC highlights the urgent need for new treatment options, as chemotherapy remains limited in long-term effectiveness for this aggressive cancer. 🔹Funding and Investment Growth: From 2019 to 2023, venture capital funding in SCLC research has shown positive trends, led by China and the U.S. This financial support, particularly in early and mid-stage developments, underscores strong industry commitment to advancing SCLC treatment options. 🔹Regulatory and Biomarker Advances: Recent FDA approvals, including those for drugs like Lurbinectedin, along with advances in biomarker discovery, are enhancing patient selection for immunotherapy, offering a more targeted approach to SCLC management. Download the free report on the SCLC landscape: https://ow.ly/GsVH50TVXNI #SCLC #OncologyResearch #Novotech